Kinaset Therapeutics Secures $103M for Severe Asthma Drug Advancement
January 13, 2026, 10:20 am
Kinaset Therapeutics obtained $103 million in Series B funding. This capital fuels the development of frevecitinib. Frevecitinib is an innovative inhaled pan-JAK inhibitor. It targets severe asthma and other serious respiratory diseases. The drug delivers potent anti-inflammatory effects directly to the lungs. It minimizes systemic exposure. This offers hope for patients with inadequate control, especially non-eosinophilic asthma. Leading life science investors RA Capital Management and Forge Life Science Partners spearheaded the round, strengthening Kinaset's board and future pipeline. This strategic investment marks a pivotal moment in addressing critical unmet needs in respiratory care.
Kinaset Therapeutics, a leading clinical-stage biopharmaceutical firm, has successfully closed an oversubscribed Series B financing round. The company secured an impressive $103 million. This substantial investment marks a critical milestone for Kinaset. It propels their innovative lead program, frevecitinib, forward. The funding targets mid-stage development of this inhaled anti-inflammatory candidate. It specifically focuses on severe asthma and other serious respiratory conditions.
The financing round garnered significant attention from top-tier life science investors. New investors RA Capital Management and Forge Life Science Partners co-led the round. They demonstrated strong confidence in Kinaset's vision and pipeline. Additional new participants included EQT Life Sciences, Vivo Capital, Schroders Capital, Willett Advisors, Pictet Alternative Advisors, and Sixty Degree Capital. Existing backers also recommitted. These included Atlas Venture, 5AM Ventures, and Gimv. This robust investor syndicate underscores the perceived value and potential of Kinaset's therapeutic approach.
Proceeds from the Series B funding will directly advance frevecitinib. The company plans to move the drug through crucial Phase 2 studies. This includes a dedicated Phase 2 dose-ranging clinical trial. This trial will enroll patients suffering from severe asthma. The investment also supports broader research and development efforts. Kinaset aims to build a robust pipeline of novel inhaled therapies. These therapies will target severe respiratory diseases.
Frevecitinib represents a significant advancement in respiratory medicine. It is a differentiated inhaled pan-JAK inhibitor. This design enables broad anti-inflammatory activity. The drug works directly within the lungs. Critically, it minimizes systemic exposure. This localized action is a key differentiator. It aims to reduce potential side effects associated with systemically delivered anti-inflammatory agents.
Asthma remains a pervasive global health challenge. Millions worldwide live with this chronic respiratory condition. A large proportion of these patients find their disease inadequately controlled. Standard maintenance therapies often fall short. Severe asthma, in particular, presents complex treatment hurdles. Frevecitinib seeks to address these unmet needs. It offers a potential new option for a wide population of severe asthma patients.
A particularly underserved group includes patients with non-eosinophilic asthma. These individuals often have fewer effective treatment choices available. Frevecitinib’s broad mechanism of action offers hope. It targets various inflammatory pathways. This broad activity could benefit both Th2- and Th1-driven inflammation. This makes it a promising candidate for this challenging patient subgroup.
The formulation of frevecitinib is also a key feature. It is developed as a dry-powder, single-capsule product. Patients administer it via a dry powder inhaler. This delivery system ensures therapeutic lung concentrations. Concurrently, it limits drug levels in the bloodstream. This precision delivery enhances safety and efficacy.
Frevecitinib targets multiple Janus kinase (JAK) proteins. It inhibits JAK1, JAK2, JAK3, and TYK2. This pan-JAK inhibition is central to its anti-inflammatory effects. The breadth of its targets suggests comprehensive modulation of inflammatory processes within the lungs. Early clinical data has shown promise. The drug demonstrates an excellent safety profile. This provides a strong foundation for its continued development.
Beyond funding, the Series B round also led to strategic additions to Kinaset’s Board of Directors. Three new directors joined the board. Henry Stusnick from RA Capital Management brings deep investment expertise. Daniela Begolo from EQT Life Sciences adds valuable life science insights. Peter B. Silverman from Forge Life Science Partners also joins. His prior experience includes serving as Chief Operating Officer of Merus N.V., a biopharmaceutical company. These appointments strengthen Kinaset’s leadership and strategic guidance.
The company's CEO, Robert Clarke, emphasizes Kinaset’s core mission. The goal is to develop best-in-class therapeutics for severe inflammatory respiratory diseases. Frevecitinib stands out. It has the potential to benefit all patients with severe asthma. This includes those with non-eosinophilic phenotypes. These patients continue to lack safe and effective therapies. The financing represents a major step. It enables Kinaset to execute its vision. Advancing frevecitinib through Phase 2 is paramount.
The biopharmaceutical community views Kinaset as a company positioned for significant impact. Its focus on novel mechanisms for respiratory disease is critical. Inhaled anti-inflammatory agents for asthma have seen limited innovation for decades. Frevecitinib could be the first of its kind in many years. This potential breakthrough garners strong industry support. Investors recognize the critical unmet need. They see the strength of Kinaset’s team.
The strategic investment ensures Kinaset can accelerate its clinical programs. It will allow further exploration of frevecitinib's full therapeutic potential. The company is poised for growth. It aims to bring this much-needed treatment to patients globally. The advancement of frevecitinib could redefine the treatment landscape for severe asthma. It offers new hope for millions struggling with this debilitating condition. This funding round solidifies Kinaset's trajectory as a leader in respiratory therapeutics.
Kinaset Therapeutics, a leading clinical-stage biopharmaceutical firm, has successfully closed an oversubscribed Series B financing round. The company secured an impressive $103 million. This substantial investment marks a critical milestone for Kinaset. It propels their innovative lead program, frevecitinib, forward. The funding targets mid-stage development of this inhaled anti-inflammatory candidate. It specifically focuses on severe asthma and other serious respiratory conditions.
The financing round garnered significant attention from top-tier life science investors. New investors RA Capital Management and Forge Life Science Partners co-led the round. They demonstrated strong confidence in Kinaset's vision and pipeline. Additional new participants included EQT Life Sciences, Vivo Capital, Schroders Capital, Willett Advisors, Pictet Alternative Advisors, and Sixty Degree Capital. Existing backers also recommitted. These included Atlas Venture, 5AM Ventures, and Gimv. This robust investor syndicate underscores the perceived value and potential of Kinaset's therapeutic approach.
Proceeds from the Series B funding will directly advance frevecitinib. The company plans to move the drug through crucial Phase 2 studies. This includes a dedicated Phase 2 dose-ranging clinical trial. This trial will enroll patients suffering from severe asthma. The investment also supports broader research and development efforts. Kinaset aims to build a robust pipeline of novel inhaled therapies. These therapies will target severe respiratory diseases.
Frevecitinib represents a significant advancement in respiratory medicine. It is a differentiated inhaled pan-JAK inhibitor. This design enables broad anti-inflammatory activity. The drug works directly within the lungs. Critically, it minimizes systemic exposure. This localized action is a key differentiator. It aims to reduce potential side effects associated with systemically delivered anti-inflammatory agents.
Asthma remains a pervasive global health challenge. Millions worldwide live with this chronic respiratory condition. A large proportion of these patients find their disease inadequately controlled. Standard maintenance therapies often fall short. Severe asthma, in particular, presents complex treatment hurdles. Frevecitinib seeks to address these unmet needs. It offers a potential new option for a wide population of severe asthma patients.
A particularly underserved group includes patients with non-eosinophilic asthma. These individuals often have fewer effective treatment choices available. Frevecitinib’s broad mechanism of action offers hope. It targets various inflammatory pathways. This broad activity could benefit both Th2- and Th1-driven inflammation. This makes it a promising candidate for this challenging patient subgroup.
The formulation of frevecitinib is also a key feature. It is developed as a dry-powder, single-capsule product. Patients administer it via a dry powder inhaler. This delivery system ensures therapeutic lung concentrations. Concurrently, it limits drug levels in the bloodstream. This precision delivery enhances safety and efficacy.
Frevecitinib targets multiple Janus kinase (JAK) proteins. It inhibits JAK1, JAK2, JAK3, and TYK2. This pan-JAK inhibition is central to its anti-inflammatory effects. The breadth of its targets suggests comprehensive modulation of inflammatory processes within the lungs. Early clinical data has shown promise. The drug demonstrates an excellent safety profile. This provides a strong foundation for its continued development.
Beyond funding, the Series B round also led to strategic additions to Kinaset’s Board of Directors. Three new directors joined the board. Henry Stusnick from RA Capital Management brings deep investment expertise. Daniela Begolo from EQT Life Sciences adds valuable life science insights. Peter B. Silverman from Forge Life Science Partners also joins. His prior experience includes serving as Chief Operating Officer of Merus N.V., a biopharmaceutical company. These appointments strengthen Kinaset’s leadership and strategic guidance.
The company's CEO, Robert Clarke, emphasizes Kinaset’s core mission. The goal is to develop best-in-class therapeutics for severe inflammatory respiratory diseases. Frevecitinib stands out. It has the potential to benefit all patients with severe asthma. This includes those with non-eosinophilic phenotypes. These patients continue to lack safe and effective therapies. The financing represents a major step. It enables Kinaset to execute its vision. Advancing frevecitinib through Phase 2 is paramount.
The biopharmaceutical community views Kinaset as a company positioned for significant impact. Its focus on novel mechanisms for respiratory disease is critical. Inhaled anti-inflammatory agents for asthma have seen limited innovation for decades. Frevecitinib could be the first of its kind in many years. This potential breakthrough garners strong industry support. Investors recognize the critical unmet need. They see the strength of Kinaset’s team.
The strategic investment ensures Kinaset can accelerate its clinical programs. It will allow further exploration of frevecitinib's full therapeutic potential. The company is poised for growth. It aims to bring this much-needed treatment to patients globally. The advancement of frevecitinib could redefine the treatment landscape for severe asthma. It offers new hope for millions struggling with this debilitating condition. This funding round solidifies Kinaset's trajectory as a leader in respiratory therapeutics.